New York Blood Center Enterprises (NYBCe) has acquired cell and gene therapy development and manufacturing facilities, along with technologies and equipment, from Talaris Therapeutics in Texas and Kentucky. This strategic move, combined with NYBCe’s Comprehensive Cell Solutions (CCS) network, strengthens their position in offering a fully integrated cell and gene therapy development and manufacturing solution for the continental United States. These state-of-the-art facilities provide expanded collection capabilities and GMP manufacturing capacity, facilitating the fast-tracking of life-saving therapies to hospital systems.
New York Blood Center Enterprises (NYBCe) and Talaris Therapeutics, Inc. (Nasdaq: TALS) (“Talaris”) announced today NYBCe’s acquisition of commercial-scale cell and gene therapy development and manufacturing facilities, as well as certain technologies and equipment from Talaris in Houston, Texas and Louisville, Kentucky. The acquisition of both locations, combined with NYBCe’s Comprehensive Cell Solutions (CCS) vast cell sourcing and collection network, accelerates the delivery of a fully integrated vein-to-vein cell and gene therapy development and manufacturing solution for the continental United States (US), capable of serving the biopharma industry and large hospital systems.
“I am exceptionally pleased with this strategic expansion of our CCS portfolio,” said Christopher D. Hillyer, MD, President and Chief Executive Officer at NYBCe, “which now allows NYBCe to have in-house start-to-finish cell and gene therapy, and regenerative medicine, development and manufacturing capabilities. Our new facilities and expert teams are located within key geographies, with best-in-class GMP manufacturing, and a close-to-patient transportation network as well as leading academic medical centers, which will allow us to fast-track lifesaving therapies to hospital systems.”
Both state-of-the-art facilities offer space for autologous and allogeneic cell sourcing and collection, expanding NYBCe’s large collection footprint and broad donor base. The Louisville, Kentucky facility adds approximately 20,000 sq. ft. with quality control and Phase 3-fitted GMP manufacturing capacity. The space provides ISO 7 cleanrooms, vast GMP capacity, cryopreservation, and storage and warehouse space, a robust digital chain of identity systems, supported by rigorous testing and release procedures. The Houston, Texas facility offers another 6,000 sq. ft. of analytical and process development capacity enhancing NYBCe’s expertise in broad analytical methodologies across cell types, viral vectors, mRNA, and gene expression analysis.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
“We are delighted to have this portfolio of CMC assets become a part of CCS,” said Mary Kay Fenton, President and Interim Chief Executive Officer, Talaris Therapeutics, Inc.
“CCS’ acquisition will improve the process of drug development and delivery for patients with life-threatening cancers, as well as severe blood and genetic disorders. We look forward to bringing on additional talent from the cell and gene therapy hubs of Houston and Louisville and providing the highest quality cell and gene therapies for biopharma companies and hospitals throughout the US,” said Jay Mohr, Executive Vice President, Chief Business Officer, NYBCe.
Source: Bio Space
